Websterrogers Financial Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$216K Sell
180
-64
-26% -$65.4K 0.06% 95
2026
Q1
$224K Sell
244
-39
-14% -$39.5K 0.06% 86
2025
Q4
$304K Hold
283
0.09% 69
2025
Q3
$216K Sell
283
-27
-9% -$20.1K 0.06% 86
2025
Q2
$242K Hold
310
0.08% 73
2025
Q1
$256K Sell
310
-174
-36% -$145K 0.09% 70
2024
Q4
$374K Sell
484
-16
-3% -$13.2K 0.13% 53
2024
Q3
$443K Sell
500
-100
-17% -$89.9K 0.16% 49
2024
Q2
$543K Hold
600
0.19% 48
2024
Q1
$467K Hold
600
0.17% 50
2023
Q4
$350K Hold
600
0.15% 53
2023
Q3
$322K Sell
600
-19
-3% -$9.79K 0.14% 56
2023
Q2
$290K Hold
619
0.13% 54
2023
Q1
$213K Hold
619
0.1% 58
2022
Q4
$226K Hold
619
0.11% 57
2022
Q3
$200K Sell
619
-80
-11% -$25.3K 0.11% 51
2022
Q2
$227K Hold
699
0.11% 55
2022
Q1
$205K Buy
+699
New +$180K 0.1% 65

Other funds holding LLY

Websterrogers Financial Advisors's LLY Position: Q2 2026 in Review

Websterrogers Financial Advisors reduced its Eli Lilly (LLY) stake by 26% in Q2 2026, selling an estimated $65.4K and leaving 180 shares worth $216K. The position accounts for 0.06% of the portfolio, ranked #95.

Websterrogers Financial Advisors first reported a position in LLY in Q1 2022 and has held it in 18 quarters since. The position peaked at $543K in Q2 2024. 961 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Websterrogers Financial Advisors held 180 shares of Eli Lilly worth $216K as of Q2 2026.
  • Websterrogers Financial Advisors sold 64 Eli Lilly shares in Q2 2026, an estimated $65.4K.
  • Eli Lilly made up 0.06% of Websterrogers Financial Advisors's portfolio in Q2 2026, its #95 holding.
  • Websterrogers Financial Advisors first reported a position in Eli Lilly in Q1 2022 and has held it in 18 quarters since.
  • Websterrogers Financial Advisors's Eli Lilly position peaked at $543K in Q2 2024.
  • 961 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Websterrogers Financial Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.